Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
Dharmesh Gopalakrishnan, Vadim S. Koshkin, Moshe Chaim Ornstein, et al.
Therapeutics and Clinical Risk Management (2018) Vol. Volume 14, pp. 1019-1040
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles, Se Hoon Park, Éric Voog, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 13, pp. 1218-1230
Open Access | Times Cited: 1155
Mouse and human urothelial cancer organoids: A tool for bladder cancer research
Jasper Mullenders, Evelien de Jongh, Anneta Brousali, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 10, pp. 4567-4574
Open Access | Times Cited: 230
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD
Kate A. Markey, Jonas Schlüter, Antonio L. C. Gomes, et al.
Blood (2020) Vol. 136, Iss. 1, pp. 130-136
Open Access | Times Cited: 116
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Paulo Gustavo Bergerot, Peter Lamb, Evelyn N. Wang, et al.
Molecular Cancer Therapeutics (2019) Vol. 18, Iss. 12, pp. 2185-2193
Closed Access | Times Cited: 110
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Sangeeta Goswami, Yulong Chen, Swetha Anandhan, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 548
Closed Access | Times Cited: 105
Molecular profiles of small cell lung cancer subtypes: Therapeutic implications
Anna Schwendenwein, Zsolt Megyesfalvi, Nándor Bárány, et al.
Molecular Therapy — Oncolytics (2021) Vol. 20, pp. 470-483
Open Access | Times Cited: 95
Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
Ali Raza Khaki, Ang Li, Leonidas Nikolaos Diamantopoulos, et al.
Cancer (2019) Vol. 126, Iss. 6, pp. 1208-1216
Open Access | Times Cited: 84
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
Dongkui Song, Thomas Powles, Lei Shi, et al.
The Journal of Pathology (2019) Vol. 249, Iss. 2, pp. 151-165
Open Access | Times Cited: 83
Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy
Solmaz Ohadian Moghadam, Mohammad Reza Nowroozi
Scandinavian Journal of Immunology (2019) Vol. 90, Iss. 6
Open Access | Times Cited: 63
Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer
Amira Abugomaa, Mohamed Elbadawy, Hideyuki Yamawaki, et al.
Cells (2020) Vol. 9, Iss. 1, pp. 235-235
Open Access | Times Cited: 60
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
Ali Raza Khaki, Ang Li, Leonidas Nikolaos Diamantopoulos, et al.
European Urology Oncology (2021) Vol. 4, Iss. 3, pp. 464-472
Open Access | Times Cited: 54
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
Abirami Sivapiragasam, Prashanth Ashok Kumar, Ethan Sokol, et al.
Cancer Medicine (2020) Vol. 10, Iss. 1, pp. 53-61
Open Access | Times Cited: 46
Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions
Abolfazl Maghrouni, Maryam Givari, Mohammad Jalili‐Nik, et al.
International Immunopharmacology (2021) Vol. 93, pp. 107403-107403
Closed Access | Times Cited: 40
Pro-Tumorigenic Effect of Continuous Cromolyn Treatment in Bladder Cancer
Lucija Franković, Marina Degoricija, Ivana Gabela, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1619-1619
Open Access
Disulfidptosis related immune genes drive prognostic model development and tumor microenvironment characterization in bladder urothelial carcinoma
Shenchao Guo, Guangjia Lv, Hengyue Zhu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice
Marina Degoricija, Jelena Korać-Prlić, Katarina Vilović, et al.
Journal of Translational Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 35
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC
Bernadett Szabados, F. Guerrero-Ramos, Enrique Grande, et al.
Oncology and Therapy (2025)
Open Access
Targeting Stat3 signaling impairs the progression of bladder cancer in a mouse model
Jelena Korać-Prlić, Marina Degoricija, Katarina Vilović, et al.
Cancer Letters (2020) Vol. 490, pp. 89-99
Closed Access | Times Cited: 32
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
Stepan M. Esagian, Ali Raza Khaki, Leonidas Nikolaos Diamantopoulos, et al.
BJU International (2021) Vol. 128, Iss. 2, pp. 196-205
Open Access | Times Cited: 25
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Dimitrios Makrakis, Dimitra Rafailia Bakaloudi, Rafee Talukder, et al.
Clinical Genitourinary Cancer (2022) Vol. 21, Iss. 2, pp. 286-294
Closed Access | Times Cited: 18
The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies
Rachel Daher, Andrew Ruplin, Shilpa Gupta, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 200, pp. 104420-104420
Closed Access | Times Cited: 3
Updates and novel treatments in urothelial carcinoma
Kirollos S. Hanna
Journal of Oncology Pharmacy Practice (2018) Vol. 25, Iss. 3, pp. 648-656
Closed Access | Times Cited: 30
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
Haris Zahoor, M.C. Mir, Pedro Barata, et al.
Investigational New Drugs (2019) Vol. 37, Iss. 6, pp. 1231-1238
Closed Access | Times Cited: 29
Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer
Fangdie Ye, Yingchun Liang, Cheng Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Clinical Genitourinary Cancer (2022) Vol. 20, Iss. 5, pp. e440-e452
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top